How Much HGH Per Day Is a Typical Dose?

A typical prescribed dose of human growth hormone (HGH) falls in the range of roughly 0.2 to 0.5 mg per day for adults with growth hormone deficiency, while children generally receive weight-based doses of about 0.025 to 0.05 mg per kilogram of body weight per day. Those numbers shift considerably depending on the condition being treated, the patient’s age, and how their body responds, so “typical” is more of a starting corridor than a fixed target. Off-label use for bodybuilding or anti-aging operates in a different and less standardized world altogether.

Pediatric Doses and Why They Vary by Diagnosis

Children prescribed recombinant human growth hormone (rhGH) receive doses calculated by body weight, and the specific range depends on the underlying reason for treatment. For children with growth hormone deficiency, the standard window is about 0.025 to 0.05 mg/kg/day.¹ These doses have been described as similar to or slightly above the body’s own physiologic requirements, meaning they approximate what a healthy pituitary gland would naturally produce.²

Children born small for gestational age or with idiopathic short stature tend to fall into a similar range, roughly 0.025 to 0.05 mg/kg/day. Girls with Turner syndrome, however, often receive a higher dose, in the range of 0.04 to 0.06 mg/kg/day, because they tend to require more GH to achieve a meaningful growth response.¹ To put these numbers in concrete terms, a 30-kilogram child with GH deficiency might receive somewhere around 0.75 to 1.5 mg per day, while a child with Turner syndrome at the same weight could be on 1.2 to 1.8 mg per day.

The weight-based system means the absolute daily dose climbs as a child grows. That ongoing escalation is one reason treatment costs are steep and rise over time: annual costs for a 30 kg child have been estimated at $15,000 to $20,000, with adolescent treatment potentially reaching $50,000 per year.³ That financial pressure feeds directly into adherence problems, which are common and measurably impair growth outcomes.

Adult Doses Start Lower and Get Adjusted

Adults with growth hormone deficiency are dosed differently from children. Rather than a fixed weight-based formula, the current standard is to start low and titrate upward based on blood levels and how the patient feels. A common starting dose is around 0.1 to 0.2 mg per day, gradually increased over weeks to months. In clinical trials, maintenance doses after titration have landed in the neighborhood of 0.45 to 0.55 mg per day, depending on whether the dose was individualized or fixed.⁴

The shift toward individualized dosing is a direct result of side-effect experience. In one study comparing a higher fixed-dose group with an individually titrated group, side effects occurred in about 70% of the fixed-dose patients versus 30% of those on titrated doses, even though the two groups achieved similar improvements in body composition, blood pressure, and glucose metabolism.⁴ The individualized group ended up on about 0.45 mg/day compared to 0.55 mg/day in the fixed-dose group. That gap sounds small, but it translated into dramatically fewer complaints.

A Japanese trial of adult GH replacement showed similarly lower maintenance doses with individualized titration, averaging around 0.008 mg/kg/day, with comparable improvements in body fat and lean mass to the fixed-dose group.⁵ These numbers underscore a consistent theme in GH therapy: more is not necessarily better, and finding the lowest effective dose matters.

How Doctors Track Whether a Dose Is Right

The primary lab marker used to adjust GH dosing is insulin-like growth factor I, or IGF-I. The liver produces IGF-I in response to circulating growth hormone, and because GH itself pulses unpredictably throughout the day, measuring IGF-I gives a more stable picture of overall GH activity. The practical target is to bring a patient’s IGF-I level into the upper half of the normal range for their age and sex.⁶

There is an honest limitation here: researchers have noted that the evidence linking specific IGF-I levels to actual clinical outcomes is thin. The upper-half-of-normal target is based on analysis of available data rather than on large trials proving that hitting a particular number translates to a specific health benefit.⁶ In practice, clinicians use IGF-I alongside clinical signs: Is the patient retaining fluid? Is their blood sugar creeping up? Are they gaining lean mass and losing trunk fat? The dose gets nudged up or down accordingly, making GH replacement something closer to an ongoing calibration than a one-time prescription.

Why Older Adults Need Much Less

Natural GH secretion peaks around puberty and then declines steadily. By age 60, many adults produce so little GH over a 24-hour period that their output is essentially indistinguishable from patients with pituitary damage.⁷ This progressive decline is sometimes called the “somatopause,” and it parallels changes in body composition and metabolism that resemble clinical GH deficiency: more abdominal fat, less muscle, altered cholesterol levels.

When older adults are given GH, they tend to be far more sensitive to it than younger patients. That means the doses must be very low, increased slowly, and carefully tailored.⁷ An older patient might start at half or even a third of the dose a 30-year-old would receive, because the same absolute dose produces a proportionally larger spike in IGF-I and a higher chance of fluid retention, joint pain, and blood sugar problems. This is one of the most common dosing mistakes in anti-aging clinics, where protocols designed for younger adults get applied to 60- or 70-year-olds with predictably unpleasant results.

When and How Injections Are Given

Growth hormone is given by subcutaneous injection, typically once a day. Subcutaneous and intramuscular routes produce similar peak blood levels about two hours after injection and generate equivalent rises in IGF-I.⁸ Subcutaneous injection won out as the default because it is less painful, easier to self-administer, and does not require rotating between muscle sites.

The timing of the injection matters, at least in theory. In people with normal pituitary function, the largest natural GH surge happens shortly after the onset of sleep. Researchers have examined whether mimicking that pattern by injecting GH in the evening produces different metabolic effects than a morning injection.⁹ In practice, most clinicians recommend evening or bedtime injection to approximate the body’s normal rhythm, though the clinical difference between morning and evening dosing is considered modest. Consistency matters more than the specific hour on the clock.

Side Effects Are Dose-Dependent

The side-effect profile of GH therapy tracks closely with dose. At therapeutic replacement levels, serious problems are uncommon. As doses climb, the same symptoms that characterize acromegaly (a condition of chronic GH excess) start appearing. These include elevated blood sugar, high blood pressure, joint pain, and carpal tunnel syndrome.¹⁰

Fluid retention is one of the earliest and most common complaints. Swelling in the hands, feet, and ankles can show up within days of starting therapy or increasing a dose, and it is a reliable signal that the dose may be too high. Glucose intolerance and insulin resistance also scale with dose, which is particularly relevant for patients who already have prediabetes or metabolic syndrome.¹¹ These effects tend to be reversible when the dose is reduced, which is another argument for the low-and-slow titration approach.

Joint pain deserves a specific mention because it is often the symptom that sends patients back to their doctor first. GH stimulates cartilage and connective tissue growth, and at supraphysiologic doses the resulting tissue swelling can compress nerves (hence carpal tunnel) or create stiffness in the fingers, wrists, and knees. For someone using GH outside of medical supervision, persistent joint pain is a strong cue that the dose is too high.

Off-Label and Non-Medical Use

Outside of clinical settings, GH is widely used for bodybuilding, athletic performance, and anti-aging purposes. The doses in these contexts vary enormously. Performance-enhancement doses reportedly range from about 2 IU per day at the low end up to 10 IU per day among some professional bodybuilders. To translate those units into milligrams, 1 IU of somatropin equals roughly 0.33 mg, so 2 IU is about 0.66 mg and 10 IU is about 3.3 mg. The upper end of that range is several times higher than what a clinician would prescribe for adult GH deficiency, which explains the high rate of side effects reported in bodybuilding communities.

Anti-aging use tends to involve lower doses, often in the 1 to 2 IU per day range, sometimes accompanied by other peptides or secretagogues. The rationale is to nudge IGF-I levels up toward youthful ranges without causing obvious side effects. Whether this approach delivers meaningful benefits is a different question from whether the dose is safe. The clinical evidence for GH as an anti-aging intervention remains weak, and the long-term safety picture is incomplete.

It is worth noting that GH obtained outside of a pharmacy may not contain what the label claims. Underground and gray-market products vary in purity, concentration, and even the molecule itself. Someone “taking 4 IU per day” of an unverified product may be getting more, less, or something altogether different from pharmaceutical-grade somatropin. This makes dose discussions in non-medical contexts inherently unreliable.

Once-Weekly Formulations Are Changing the Math

One of the biggest practical developments in GH therapy is the arrival of long-acting formulations that replace daily injections with a single weekly shot. Two products in particular have been studied in children: somapacitan and somatrogon. In a phase 2 trial, somapacitan was tested at weekly doses of 0.04, 0.08, and 0.16 mg/kg/week against a daily GH control arm dosed at 0.034 mg/kg/day.¹² In a real-world Greek study, somatrogon was given at 0.66 mg/kg/week, compared to daily GH at about 0.23 mg/kg/week divided into six or seven doses.¹³

The weekly dose is not simply seven daily doses lumped together. These molecules are engineered to release GH slowly, so the pharmacokinetics differ from a daily injection. The IGF-I profile across the week looks different too: instead of a sharp peak a few hours after injection followed by a trough before the next day’s shot, weekly formulations produce a more gradual rise and fall. Whether that different exposure pattern matters for long-term growth outcomes is still being studied, but early results show height velocity comparable to daily therapy.

For families dealing with years of daily injections in a child who may be frightened of needles, reducing the injection burden from 365 shots a year to 52 is a substantial quality-of-life improvement. Adherence to daily GH is a well-documented problem, and missed doses accumulate into meaningfully impaired growth over time.³ Weekly dosing does not eliminate non-compliance, but it lowers the number of opportunities to miss.

GH Secretagogues and Oral Alternatives

Rather than injecting GH directly, some approaches aim to stimulate the body’s own pituitary gland to release more. GH secretagogues are compounds that trigger GH release from within. One of the most studied is MK-677 (ibutamoren), an oral compound that has been investigated in research settings at a dose of 25 mg daily in obese men.¹⁴ Secretagogues raise GH levels indirectly by acting on ghrelin receptors, and the resulting GH release includes the full range of natural GH isoforms rather than the single 22-kilodalton form found in injectable somatropin.

These compounds are popular in bodybuilding and anti-aging communities because they are taken by mouth, avoiding the hassle and cost of injection. However, they come with their own side-effect profile, including increased appetite (ghrelin receptor stimulation does exactly what you’d expect to hunger), water retention, and potential effects on blood sugar. They are not approved as GH replacement therapy in most countries, and comparing their “equivalent dose” to injectable GH is not straightforward because the GH release pattern is pulsatile and varies from person to person.

Subcutaneous Injection Technique and Absorption

For daily injectable GH, the standard route is subcutaneous injection into the abdomen, thigh, or upper arm. Studies comparing subcutaneous and intramuscular routes found that peak GH levels in blood were similar, occurring about two hours after injection regardless of route, and the downstream rise in IGF-I was equivalent.¹⁵ IGF-I levels roughly tripled after four days of injections in both treatment groups, confirming that the absorption pathway does not meaningfully alter the biological response.

Rotating injection sites is recommended to prevent lipohypertrophy, a localized buildup of fatty tissue that can develop at frequently used injection spots. Beyond being cosmetically noticeable, lipohypertrophy can change how quickly GH is absorbed from that site, introducing unpredictable variation in blood levels. Patients who inject in the same spot every night may unknowingly alter their effective dose over months. Most clinicians suggest rotating among at least three or four sites on a regular schedule.

Modern pen devices have made self-injection considerably easier than it was in the early days of GH therapy. Pre-filled pens with fine-gauge needles require minimal preparation and cause less discomfort than the syringes and vials used decades ago. For pediatric patients especially, these devices can make the difference between a child tolerating nightly injections and a family struggling with compliance every evening.